| Drug-Target Information | ||||||||
|---|---|---|---|---|---|---|---|---|
| Drug Name | Target Name | Drug Type | Target Type | Source | Drug MeSHID | Interaction Score | Drug Status | Target Action |
| selumetinib | erk activator kinase 1 | NA | Clinical trial target | TTD , DGIDB | Malignant Neoplasms[MeSHID:D009369] Neurofibromatosis 1[MeSHID:D009456] Plexiform Neurofibroma[MeSHID:D018318] Severe Acute Respiratory Syndrome[MeSHID:D045169] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Middle East Respiratory Syndrome[MeSHID:D018352] |
0.87 | phase 3 | allosteric modulator |
| selumetinib | dual specificity mitogen-activated protein kinase kinase 1 | small molecule | NA | drugbank , DGIDB | Malignant Neoplasms[MeSHID:D009369] Neurofibromatosis 1[MeSHID:D009456] Plexiform Neurofibroma[MeSHID:D018318] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] melanoma[MeSHID:D008545] Thyroid carcinoma[MeSHID:D013964] Non-Small Cell Lung Carcinoma[MeSHID:D002289] |
0.87 | approved,investigational | inhibitor |
| selumetinib | erk activator kinase 1 | NA | Clinical trial target | TTD , DGIDB | Malignant Neoplasms[MeSHID:D009369] Neurofibromatosis 1[MeSHID:D009456] Plexiform Neurofibroma[MeSHID:D018318] Severe Acute Respiratory Syndrome[MeSHID:D045169] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Middle East Respiratory Syndrome[MeSHID:D018352] |
0.87 | phase 3 | inhibitor |
| selumetinib | erk activator kinase 1 | NA | Clinical trial target | TTD , DGIDB | Malignant Neoplasms[MeSHID:D009369] Neurofibromatosis 1[MeSHID:D009456] Plexiform Neurofibroma[MeSHID:D018318] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] melanoma[MeSHID:D008545] Thyroid carcinoma[MeSHID:D013964] Non-Small Cell Lung Carcinoma[MeSHID:D002289] |
0.87 | phase 3 | allosteric modulator |
| selumetinib | erk activator kinase 1 | NA | Clinical trial target | TTD , DGIDB | Malignant Neoplasms[MeSHID:D009369] Neurofibromatosis 1[MeSHID:D009456] Plexiform Neurofibroma[MeSHID:D018318] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] melanoma[MeSHID:D008545] Thyroid carcinoma[MeSHID:D013964] Non-Small Cell Lung Carcinoma[MeSHID:D002289] |
0.87 | phase 3 | inhibitor |
| selumetinib | dual specificity mitogen-activated protein kinase kinase 1 | small molecule | NA | drugbank , DGIDB | Malignant Neoplasms[MeSHID:D009369] Neurofibromatosis 1[MeSHID:D009456] Plexiform Neurofibroma[MeSHID:D018318] Severe Acute Respiratory Syndrome[MeSHID:D045169] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Middle East Respiratory Syndrome[MeSHID:D018352] |
0.87 | approved,investigational | inhibitor,allosteric modulator |
| selumetinib | erk activator kinase 1 | NA | Clinical trial target | TTD , DGIDB | Malignant Neoplasms[MeSHID:D009369] Neurofibromatosis 1[MeSHID:D009456] Plexiform Neurofibroma[MeSHID:D018318] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] melanoma[MeSHID:D008545] Thyroid carcinoma[MeSHID:D013964] Non-Small Cell Lung Carcinoma[MeSHID:D002289] |
0.87 | phase 3 | unknown |
| selumetinib | dual specificity mitogen-activated protein kinase kinase 1 | small molecule | NA | drugbank , DGIDB | Malignant Neoplasms[MeSHID:D009369] Neurofibromatosis 1[MeSHID:D009456] Plexiform Neurofibroma[MeSHID:D018318] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] melanoma[MeSHID:D008545] Thyroid carcinoma[MeSHID:D013964] Non-Small Cell Lung Carcinoma[MeSHID:D002289] |
0.87 | approved,investigational | inhibitor,allosteric modulator |
| selumetinib | dual specificity mitogen-activated protein kinase kinase 1 | small molecule | NA | drugbank , DGIDB | Malignant Neoplasms[MeSHID:D009369] Neurofibromatosis 1[MeSHID:D009456] Plexiform Neurofibroma[MeSHID:D018318] Severe Acute Respiratory Syndrome[MeSHID:D045169] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Middle East Respiratory Syndrome[MeSHID:D018352] |
0.87 | approved,investigational | inhibitor |
| selumetinib | erk activator kinase 1 | NA | Clinical trial target | TTD , DGIDB | Malignant Neoplasms[MeSHID:D009369] Neurofibromatosis 1[MeSHID:D009456] Plexiform Neurofibroma[MeSHID:D018318] Severe Acute Respiratory Syndrome[MeSHID:D045169] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Middle East Respiratory Syndrome[MeSHID:D018352] |
0.87 | phase 3 | unknown |
| selumetinib | erk activator kinase 2 | NA | Clinical trial target | TTD , DGIDB | Malignant Neoplasms[MeSHID:D009369] Neurofibromatosis 1[MeSHID:D009456] Plexiform Neurofibroma[MeSHID:D018318] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] melanoma[MeSHID:D008545] Thyroid carcinoma[MeSHID:D013964] Non-Small Cell Lung Carcinoma[MeSHID:D002289] |
0.4 | phase 3 | inhibitor |
| selumetinib | erk activator kinase 2 | NA | Clinical trial target | TTD , DGIDB | Malignant Neoplasms[MeSHID:D009369] Neurofibromatosis 1[MeSHID:D009456] Plexiform Neurofibroma[MeSHID:D018318] Severe Acute Respiratory Syndrome[MeSHID:D045169] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Middle East Respiratory Syndrome[MeSHID:D018352] |
0.4 | phase 3 | unknown |
| selumetinib | erk activator kinase 2 | NA | Clinical trial target | TTD , DGIDB | Malignant Neoplasms[MeSHID:D009369] Neurofibromatosis 1[MeSHID:D009456] Plexiform Neurofibroma[MeSHID:D018318] Severe Acute Respiratory Syndrome[MeSHID:D045169] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Middle East Respiratory Syndrome[MeSHID:D018352] |
0.4 | phase 3 | inhibitor |
| selumetinib | dual specificity mitogen-activated protein kinase kinase 2 | small molecule | NA | drugbank , DGIDB | Malignant Neoplasms[MeSHID:D009369] Neurofibromatosis 1[MeSHID:D009456] Plexiform Neurofibroma[MeSHID:D018318] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] melanoma[MeSHID:D008545] Thyroid carcinoma[MeSHID:D013964] Non-Small Cell Lung Carcinoma[MeSHID:D002289] |
0.4 | approved,investigational | inhibitor |
| selumetinib | dual specificity mitogen-activated protein kinase kinase 2 | small molecule | NA | drugbank , DGIDB | Malignant Neoplasms[MeSHID:D009369] Neurofibromatosis 1[MeSHID:D009456] Plexiform Neurofibroma[MeSHID:D018318] Severe Acute Respiratory Syndrome[MeSHID:D045169] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Middle East Respiratory Syndrome[MeSHID:D018352] |
0.4 | approved,investigational | inhibitor |
| selumetinib | erk activator kinase 2 | NA | Clinical trial target | TTD , DGIDB | Malignant Neoplasms[MeSHID:D009369] Neurofibromatosis 1[MeSHID:D009456] Plexiform Neurofibroma[MeSHID:D018318] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] melanoma[MeSHID:D008545] Thyroid carcinoma[MeSHID:D013964] Non-Small Cell Lung Carcinoma[MeSHID:D002289] |
0.4 | phase 3 | unknown |
| click here to return to the previous page | ||||||||